News from debiopharm international sa A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 07, 2019, 10:00 ET Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America

Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding...


Nov 14, 2017, 03:00 ET EMA Grants Orphan Drug Designation to Debiopharm International SA's FGFR Inhibitor Debio 1347 in the Treatment of Biliary Tract Cancer

LAUSANNE, Switzerland, Nov. 14, 2017 /CNW/ - Debiopharm International SA (Debiopharm - http://www.debiopharm.com), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today...


Nov 06, 2017, 09:00 ET Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)

The clinical trial is in collaboration with the alliance between Merck KGaA, Darmstadt, Germany and Pfizer LAUSANNE, Switzerland, Nov. 6, 2017 /CNW/ - Debiopharm International SA (Debiopharm -...


Oct 12, 2017, 09:00 ET GenePOC Launches its new GenePOC™ GBS DS Test

GenePOC announces the launch of its Group B Streptococcus Direct Swab (DS) molecular test in Europe QUÉBEC CITY, Oct. 12, 2017 /CNW/ - GenePOC, Inc. (GenePOC), a member of the Debiopharm Group, is...


Jun 15, 2017, 08:00 ET Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN

A total of 96 patients randomized in France and Switzerland. Results expected in Q1 2019. LAUSANNE, Switzerland, June 15, 2017 /CNW/ - Debiopharm International SA (Debiopharm -...


Jun 01, 2017, 09:00 ET GenePOC Announces FDA Clearance for Revogene™ Instrument and its GBS LB Test

QUÉBEC CITY and LAUSANNE, Switzerland, June 1, 2017 /CNW/ - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group ...


Jun 01, 2017, 08:00 ET Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284

Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors LAUSANNE, Switzerland, June 1, 2017 /CNW/ - Debiopharm International SA (Debiopharm -...


Feb 02, 2017, 03:00 ET GenePOC Announces Product Launch in Europe and Middle East

GenePOC announces the commercialization of its Clostridium difficile and Group B Strep molecular tests in Europe, along with onboarding additional partners to cover the EMEA market QUÉBEC CITY and...


Jan 10, 2017, 10:00 ET Debiopharm International SA Announces Positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI Patients

The study in patients with staphylococcal Acute Bacterial Skin and Skin Structure Infections (ABSSSI) demonstrated efficacy and safety of the first in class staphylococcal-selective antibiotic Debio...


Oct 25, 2016, 09:00 ET Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450

Debiopharm has completed a phase II study in ABSSSI, received Orphan Drug Designation from the EC for the treatment of osteomyelitis and demonstrated the protective effect of Debio 1450 on the gut...


Oct 20, 2016, 08:05 ET Debiopharm International SA Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer in Cancer Immunotherapy

This joint effort will initially focus on a Phase I/Ib trial in patients with Lung Cancer to assess safety and preliminary efficacy of Debio 1143 in combination with avelumab LAUSANNE, Switzerland,...


Oct 07, 2016, 03:00 ET The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2016 JCA-Mauvernay Award

The 'JCA-Mauvernay Award 2016' is awarded to Doctors Hidewaki Nakagawa and Hiroyuki Seimiya LAUSANNE, Switzerland, Oct. 7, 2016 /CNW/ - Debiopharm Group™(www.debiopharm.com), a Swiss-based global...


Aug 30, 2016, 11:31 ET Debiopharm Invests Double Digit Millions in the Canadian startup GenePOC, Specialized in the Development of Rapid Diagnostic Tests

GenePOC, which has just received CE marking for its first bacteriological test, will start commercialization in Europe this autumn, and Debiopharm will set up a future production line in Martigny...